This study is to evaluate the usability and patient tolerability for microtherapeutic dosing of commercially available ocular medication via the Eyenovia microdose delivery system (MiDD)
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Enrollment
30
Latanoprost ophthalmic solution administered as a microdose spray
Latanoprost ophthalmic solution administered as an eyedrop
Clinica de Ojos Orillac-Calvo
Panama City, Panama
Successful microtherapeutic administration to the ocular surface
Cumulative percent of cases in which microdose medication is delivered to the ocular surface as evaluated by the treating physician and an independent observer
Time frame: Treatment Day 3
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.